Allergan

Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

Retrieved on: 
Tuesday, June 6, 2023

SAN MATERO, Calif. and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance.

Key Points: 
  • SAN MATERO, Calif. and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance.
  • He will also ensure that the Company upholds the highest levels of clinical quality compliance.
  • “As we progress our clinical programs, regulatory strategy will be critical for Kronos Bio’s continued success,” said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
  • I’m confident that Marc will make meaningful contributions to Kronos Bio as we plan for the future of KB-0742 and lanraplenib as well as our discovery programs.”
    Dr. Besman joins Kronos Bio from Coherus BioSciences where he served as Senior Vice President of Regulatory Affairs.

Cognoa Announces Leadership Expansion with Strategic Hires

Retrieved on: 
Thursday, June 1, 2023

PALO ALTO, Calif., June 1, 2023 /PRNewswire/ -- Cognoa, a leading pediatric behavioral health company, today announced the expansion of its leadership team supporting the commercialization of Canvas Dx, the first and only FDA authorized diagnostic that gives diverse providers the ability to diagnose or rule out autism in children ages 1.5 to 6 years at risk of developmental delay.

Key Points: 
  • "We are excited to announce the expansion of our leadership team at Cognoa as we continue to accelerate our commercialization efforts of Canvas Dx," said Dr. Sharief Taraman, CEO of Cognoa.
  • Dr. Pollard will establish and direct Cognoa's medical affairs team to execute the broad availability of Canvas Dx.
  • Pollard held several leadership positions at HealthTap and ZendyHealth.
  • Devennie has held several commercial leadership positions at Heuro Health, Tricida, and Allergan.

Advanced Medaesthetic Partners Expands Footprint Through Strategic Investment In The AgeLess Center

Retrieved on: 
Tuesday, May 23, 2023

ATLANTA, May 23, 2023 /PRNewswire/ -- Advanced Medaesthetic Partners (AMP), a leading provider of medical aesthetic solutions, announced today a growth investment in The AgeLess Center located in Atlanta.

Key Points: 
  • ATLANTA, May 23, 2023 /PRNewswire/ -- Advanced Medaesthetic Partners (AMP), a leading provider of medical aesthetic solutions, announced today a growth investment in The AgeLess Center located in Atlanta.
  • The investment will empower The AgeLess Center to expand services and enhance its state-of-the-art facilities.
  • The AgeLess Center is in the top one percent of all practices across the nation.
  • The AgeLess Center will utilize the partnership to expand its range of services, treatments and technologies, offering patients the highest quality of care and results.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Ulcerative Colitis Treatment Market to Grow Exponentially by 2029- Brandessence Market Research

Retrieved on: 
Thursday, May 18, 2023

The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.

Key Points: 
  • The Global Ulcerative Colitis Treatment Market report curated by Brandessence Market Research provides a detailed overview of the market, including its size, growth rate, and key drivers.
  • It examines various treatment options available for ulcerative colitis, including medications, surgery, and other therapies.
  • High Cost of Treatment: One of the major challenges in the ulcerative colitis treatment market is the high cost associated with the available treatment options.
  • FMT is being explored as a potential treatment option for ulcerative colitis, with ongoing clinical trials assessing its safety and efficacy.

Global Facial Injectable Market Report 2023: Sector is Expected to Reach $38.6 Billion by 2033 at a CAGR of 10.45% - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 18, 2023

The "Facial Injectable Market, By Type, By Application, By End User and by Region - Global Forecast To 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Facial Injectable Market, By Type, By Application, By End User and by Region - Global Forecast To 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global facial injectable market size was USD 12.95 billion in 2022 and is expected to reach at USD 38.6 billion by 2033 with a CAGR of 10.45% during the forecast period 2023-2033.
  • The increasing acceptance of less invasive surgeries is one of the factors contributing to market growth.
  • However, facial injectable's relative side effects and lack of permanence is expected to hinder the market growth.

Aviceda Therapeutics Appoints Biopharma and Business Senior Executive Patrick Johnson, PhD, to its Board of Directors

Retrieved on: 
Tuesday, May 16, 2023

Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.

Key Points: 
  • Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.
  • “We are thrilled to welcome Patrick to Aviceda’s board of directors as we advance our pipeline through key milestones in 2023 and beyond,” said Mohamed A. Genead, MD, CEO & President, Co-Founder of Aviceda Therapeutics.
  • Previously, he gained exceptional sell-side and buy-side transactional experience as head of business development for eye care and drug delivery at Allergan.
  • “I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialization.”

Neuronetics Announces Lisa Metzner-Rosas as SVP, Chief Marketing Officer

Retrieved on: 
Monday, May 1, 2023

“I am delighted to welcome Lisa in this key position in Neuronetics’ strategic journey,” said Keith J. Sullivan, President and CEO of Neuronetics.

Key Points: 
  • “I am delighted to welcome Lisa in this key position in Neuronetics’ strategic journey,” said Keith J. Sullivan, President and CEO of Neuronetics.
  • Prior roles include Vice President of Marketing at Obalon Therapeutics, which went public in 2016, and ZELTIQ Aesthetics.
  • “The opportunity at Neuronetics is tremendous, and I’m excited to do big things that will drive ongoing growth for the Company and our customers,” stated Lisa Metzner-Rosas.
  • The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

Retrieved on: 
Monday, April 17, 2023

BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors.

Key Points: 
  • BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors.
  • Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent.
  • “We are pleased to welcome Rob Stewart to the CorMedix Board,” said Joseph Todisco, Chief Executive Officer of CorMedix.
  • Mr. Stewart has also previously held management roles with Abbott Laboratories, Knoll Pharmaceutical Company, and Hoffmann La Roche, Inc. Mr. Stewart currently serves on the Board of Directors of Cipla Ltd and serves on the Board of Trustees for Fairleigh Dickinson University.

Faces of South Tampa Joins MedSpa Partners

Retrieved on: 
Wednesday, April 12, 2023

Located in Tampa Bay, Florida, Faces of South Tampa is widely recognized as one of the most successful medical aesthetics clinics in the United States.

Key Points: 
  • Located in Tampa Bay, Florida, Faces of South Tampa is widely recognized as one of the most successful medical aesthetics clinics in the United States.
  • Operating out of a beautifully restored century-old mansion, Faces of South Tampa combines the historic warmth and charm of South Tampa with the sophistication and energy of a cutting-edge medical aesthetics clinic.
  • From the beginning, Faces of South Tampa has resolutely adhered to a model of impeccable service combined with undeniable, superior results.
  • We are thrilled to have the Faces of South Tampa family join our larger MSP family."